PI3K Gene Mutation clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.
at UC Irvine UCSD
Our lead scientists for PI3K Gene Mutation research studies include David E. Piccioni.